Boston Scientific Securities Fraud Lawsuit
Analysis based on 71 articles · First reported Mar 31, 2026 · Last updated Apr 27, 2026
The class action lawsuit against Boston Scientific could negatively impact its stock price and reputation due to allegations of misleading statements. Investors who purchased Boston Scientific stock during the specified period may be entitled to compensation, potentially affecting market sentiment towards the company.
Rosen Law Firm has filed a class action lawsuit against Boston Scientific on behalf of investors who purchased common stock between July 23, 2025, and February 3, 2026. The lawsuit alleges that Boston Scientific made materially false and misleading statements and/or concealed adverse facts concerning the true state of its U.S. Electrophysiology segment. Management was reportedly aware that the segment's growth rate was unsustainable and approaching an earlier tipping point than anticipated by the market. This led to investors and analysts being surprised by Boston Scientific's net income miss and underwhelming guidance for the first half of fiscal 2026, resulting in alleged damages to investors. Philip Kim and Lawrence Rosen of Rosen Law Firm are encouraging affected investors to join the class action, with a lead plaintiff deadline of May 4, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard